Compare RNA & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | WLAC |
|---|---|---|
| Founded | 2012 | 2024 |
| Country | United States | United States |
| Employees | 391 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 184.4M |
| IPO Year | 2025 | N/A |
| Metric | RNA | WLAC |
|---|---|---|
| Price | $13.05 | $18.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $69.26 | $17.00 |
| AVG Volume (30 Days) | 180.8K | ★ 681.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | $784.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $10.13 |
| 52 Week High | $73.06 | $21.00 |
| Indicator | RNA | WLAC |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 68.48 |
| Support Level | $12.56 | $11.26 |
| Resistance Level | $14.80 | N/A |
| Average True Range (ATR) | 0.50 | 1.61 |
| MACD | 0.28 | 0.25 |
| Stochastic Oscillator | 25.01 | 71.86 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Willow Lane Acquisition Corp is a blank check company.